Intraoperative adjunctive agents in vitrectomy: Serum, cytokines, and glue

Seminars in Ophthalmology

Volumn 15, Issue 1, 2000, Pages 36-43

  Saito, Yoshihiro ^a   Tano, Yasuo ^b  

^a Hyogo Prefectural Nishinomiya Hospital   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYANOACRYLATE DERIVATIVE; CYTOKINE; FIBRIN; GLUE; THROMBIN; THROMBOCYTE CONCENTRATE; TISSUE ADHESIVE; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; HUMAN; PRIORITY JOURNAL; RETINA DETACHMENT; RETINA MACULA HOLE; SERUM; SURGICAL TECHNIQUE; TREATMENT INDICATION; VITRECTOMY;

EID: 0034016467     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.3109/08820530009037849     Document Type: Article

References (63)

1. Algvere PV, Gjotterberg M, Ollivestedt G, et al. Result of pneumatic retinopexy with air. Acta Ophthalmol. 1992;70: 632-636.
2. Algvere PV, Stenkula S, Crafoord S, et al. Sealing of retinal breaks with metal tacks. Evaluation of a new procedure in retinal attachment surgery. Acta Ophthalmol. 1986;64:421-424.
3. deJuan E Jr, McCuen BW, Machemer R. Mechanical retinal fixation using tacks. Ophthalmology. 1987;94:337-340.
4. Gilbert CE. Adhesive in retinal detachments surgery. Br J Ophthalmol. 1991;75:309-310.
5. Glaser BM, Vidaurri-Leal J, Michels RG, et al. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology. 1993;100:466-470.
6. Jaffe MJ, Oliver AP, Von Fricken MA, et al. A screening method using tissue culture for evaluation of potential retinal adhesives. Retina. 1989;9:328-333.
7. Papatheofanis FJ, Barmada R. The principles and applications of surgical adhesives. Sur Ann. 1993;25:49-81.
8. Faulborn J. Treatment of giant retinal tears after perforating injuries with vitrectomy and a cyanoacrylate tissue adhesive. Adv Ophthalmol. 1976;33:204-207.
9. Matsumoto T, Hardaway RM, Pani KC, et al. Aron alpha a Sanyo, Japanese tissue adhesive in surgery of internal organs. Am Surg. 1968;24:263-267.
10. Hida T, Sheta SM, Sheta SM, et al. Retinal toxicity of cyanoacrylate tissue adhesive in the rabbit. Retina. 1988;8: 148-153.
11. McCuen BW II, Hida T, Sheta SM. Transvitreal cyanoacrylate retinopexy in the management of complicated retinal detachment. Am J Ophthalmol. 1987;104:127-132.
12. Hanneken A, de Juan E Jr, McCuen BW II. The management of retinal detachments associated with choroidal colobomas by vitreous surgery. Am J Ophthalmol. 1991;111:271-275.
13. Sheta SM, Hida T, McCuen BW II. Cyanoacrylate tissue adhesive in the management of recurrent retinal detachment caused by macular hole. Am J Ophthalmol. 1990;109:28-32.
14. Hotta K, Hirakata A, Hida T. The management of retinal detachments associated with choroidal colobomas by vitrectomy with cyanoacrylate retinopexy. Jpn J Ophthalmol. 1998;42: 323-326.
15. Hartnett ME, Hirose T. Cyanoacrylate glue in the repair of retinal detachment associated with posterior retinal breaks in infants and children. Retina. 1998;18:125-129.
16. Hida T, Sheta SM, Proia AD, et al. Experimental transvitreal cyanoacrylate retinopexy in a primate model. Am J Ophthalmol. 1987;103:782-789.
17. Liggett PE, Cano M, Robin JB, et al. Intravitreal biocompatibility of mussel adhesive protein. A preliminary study. Retina. 1990;10:144-147.
18. Nagafuchi T. Mechanism of adhesion of polyphonolic protein and its potential for clinical application [in Japanese]. Nippon Seikei Geka Gakkai Zasshi. 1992;66:1176-1183.
19. Gass JDM. Idiopathic senile macular hole-its early stages and pathogenesis. Arch Ophthalmol. 1988;106:629-639.
20. Gass JDM. Reappraisal of biomicroscopic classification of stages of development of a macular hole. Am J Ophthalmol. 1995;119:752-759.
21. Kelly NE, Wendel RT. Vitreous surgery for idiopathic macular holes. Result of a pilot study. Arch Ophthalmol. 1991;109:654-659.
22. Wendel RT, Patel AC, Kelly NE, et al. Vitreous surgery for macular holes. Ophthalmology. 1993;100:1671-1676.
23. Ignotz RA, Massague J. Transforming growth factor-beta 2 stimulates the expression of fibronectine and collagen and their incorporation into the extracellular matrix. J Biol Chem. 1986;261:4337-4345.
24. Smiddy WE, Glaser BM, Green WR, et al. Transforming growth factor beta. A biologic chorioretinal glue. Arch Ophthalmol. 1989;107:577-580.
25. Glaser BM, Michels RG, Kuppermann BD, et al. Transforming growth factor-beta 2 for the treatment of full-thickness macular holes. A prospective randomized study. Ophthalmology. 1992;99:1162-1172.
26. Smiddy WE, Glaser BM, Thompson JT, et al. Transforming growth factor-beta 2 significantly enhances the ability to flatten the rim of subretinal fluid surrounding macular holes. Preliminary anatomic results of a multicenter prospective randomized study. Retina. 1993;13:296-301.
27. Lansing MB, Glaser BM, Liss H, et al. The effect of pars plana vitrectomy and transforming growth factor-beta 2 without epiretinal membrane peeling on full-thickness macular holes. Ophthalmology. 1993;100:868-871.
28. Thompson JT, Sjaarda RN, Glaser BM, et al. Increased intraocular pressure after macular hole surgery. Am J Ophthalmol. 1996;121:615-622.
29. Rubin JS, Glaser BM, Thompson JT, et al. Vitrectomy, fluid-gas exchange and transforming growth factor-beta-2 for the treatment of traumatic macular holes. Ophthalmology. 1995;102:1840-1845.
30. Rosa RH Jr, Glaser BM, de la Cruz Z, et al. Clinicopathologic correlation of an untreated macular hole and a macular hole treated by vitrectomy, transforming growth factor-beta 2, and gas tamponade. Am J Ophthalmol. 1996;122:853-856.
31. Childs CB, Proper JA, Tucker RF, et al. Serum contains a platelet-derived transforming growth factor. Proc Natl Acad Sci USA. 1982;79:5312-5316.
32. Campochiaro PA, Jerdan JA, Glaser BM. Serum contains Chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol. 1984;102:1830-1833.
33. deJuan E, Dickson JS, Hjelmeland L. Serum is chemotactic for retinal-derived glial cells. Arch Ophthalmol. 1988;106: 986-990.
34. Park CM, Hollenberg MJ. Induction of retinal regeneration in vivo by growth factors. Dev Biol. 1991;148:322-333.
35. Campochiaro PA, Jerdan JA, Glaser BM, et al. Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol. 1985;103:1403-1405.
36. Uchihori Y, Puro DG. Mitogenic and chemotactic effects of platelet derived growth factor on human retinal glial cells. Invest Ophthalmol Vis Sci. 1991;32:2689-2695.
37. Leschey KH, Hackett SF, Singer JH, et al. Growth factor responsiveness of human retinal pigment epithelial cells. Invest Ophthalmol Vis Res. 1990;31:839-846.
38. Funata M, Wendel RT, de la Cruz Z, et al. Clinicopathologic study of bilateral macular holes treated with pars plana vitrectomy and gas tamponade. Retina. 1992;12:289-298.
39. Pinon RM, Pastor JC, Saornil MA, et al. Intravitreal and subretinal proliferation induced by platelet-rich plasma injection in rabbits. Cur Eye Res. 1992;11:1047-1055.
40. Liggett PE, Skolik SA, Horio B, et al. Human autologous serum for the treatment of full-thickness macular holes. Ophthalmology. 1995;102:1071-1076.
41. Christmas N, Skolik SA, Howard MA, et al. Treatment of retinal breaks with autologous serum in an experimental model. Ophthalmology. 1995;102:263-271.
42. Wells JA, Gregor ZJ. Surgical treatment of full-thickness macular holes using autologous serum. Eye. 1996;10:593-599.
43. Kusaka S, Sakagami K, Kutsuna M, et al. Treatment of full-thickness macular holes with autologous serum. Jpn J Ophthalmol. 1997;41:332-338.
44. Ezra E, Aylward WG, Gregor ZJ. Membranectomy and autologous serum for the retreatment of full-thickness macular holes. Arch Ophthalmol. 1997;115:1276-1280.
45. Gaudric A, Massin P, Paques M, et al. Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol. 1995;233:549-554.
46. Ksander GA, Sawamura S, Ogawa Y, et al. The effect of platelet release on wound healing in animal models. J Am Acad Dermatol. 1990;22:781-791.
47. Gaudric A, Paques M, Massin P, et al. Use of autologous platelet concentrate in macular hole surgery: report of 77 cases. Dev Ophthalmol. 1997;29:30-35.
48. Korobelnik JF, Hannouche D, Belayachi N, et al. Autologous platelet concentrate as an adjunct in macular hole healing: a pilot study. Ophthalmology. 1996;103:590-594.
49. Faude F, Edel E, Dannhauer M, et al. Autologous thrombocyte administration in treatment of idiopathic macular foramen. Ophthalmologe. 1997;94:877-881.
50. Gehring S, Hoerauf H, Laqua H, et al. Preparation of autologous platelets for the ophthalmologic treatment of macular holes. Transfusion. 1999;39:144-148.
51. Miniham M, Cleary PE. Autologous platelet concentrate in the surgical management of macular holes. Dev Ophthalmol. 1997;29:36-43.
52. Miniham M, Goggin M, Cleary PE. Surgical management of macular holes: results using gas tamponade alone, or in combination with autologous platelet concentrate, or transforming growth factor beta 2. Br J Ophthalmol. 1997;81: 1073-1079.
53. Alving BM, Weinstein MJ, Finlayson JS, et al. Fibrin sealant: summary of a conference on characteristics and clinical uses. Transfusion. 1995;35:783-790.
54. Coleman DJ, Lucas BC, Fleischman JA, et al. A biologic tissue adhesive for vitreoretinal surgery. Retina. 1988;8:250-256.
55. Tilanus MA, Deutman AF. Full-thickness macular holes treated with vitrectomy and tissue glue. Int Ophthalmol. 1994-95;18:355-358.
56. Hackett SF, Singer JH, Leschey KH, et al. Thrombin is a stimulator of retinal pigment epithelial cell proliferation. Exp Eye Res. 1991;53:95-100.
57. Vine AK, Johnson MW. Thrombin in the management of full thickness macular holes. Retina. 1996;16:474-478.
58. Olsen TW, Sternberg P, Martin DF, et al. Postoperative hypopyon after intravitreal bovine thrombin for macular hole surgery. Am J Ophthalmol. 1996;121:575-577.
59. Smiddy WE, Pimentel S, Williams GA. Macular hole surgery without using adjunctive additives. Ophthalmic Surg Lasers. 1997;28:713-717.
60. Thompson JT, Smiddy WE, Williams GA, et al. Comparison of recombinant transforming growth factor-beta-2 and placebo as an adjunctive agent for macular hole surgery. Ophthalmology. 1998;105:700-706.
61. Olsen TW, Sternberg P Jr, Capone A Jr, et al. Macular hole surgery using thrombin-activated fibrinogen and selective removal of the internal limiting membrane. Retina. 1998;18:322-329.
62. Lewis JM, Park I, Ohji M, et al. Diamond-dusted silicon cannula for membrane separation during vitreous surgery. Am J Ophthalmol. 1997;124:552-554.
63. Saito Y, Hirata Y, Hayashi A, et al. The Visual performance and metamorphopisa of patients with macular holes. Arch Ophthalmol. 2000;118:41-46.